TABLE 2C.
10‐year CI of an SMN and competing events and event‐free survival according to radio‐ and chemotherapy
| Secondary malignancies | Competing events | Event‐free survival | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Parameters | Pts. | Events | 10‐year CI | p‐Value | Events | 10‐year CI | p‐Value | 10‐year EFS | p‐value |
| Cyclophosphamide | |||||||||
| < 3.000 mg/m2 | 82 | 1 | 8.1% ± 7.7% | 0.468 | 19 | 27.1% ± 5.4% | 64.8 ± 9.0% | ||
| ≥3.000 mg/m2 | 1384 | 18 | 1.0% ± 0.3% | 291 | 22.7% ± 1.2% | 0.193 | 76.3 ± 1.2% | 0.144 | |
| Cranial radiotherapy | |||||||||
| Yes | 671 | 14 | 1.2% ± 0.5% | 0.295 | 190 | 29.0% ± 1.8% | <0.001 | 69.7 ± 1.8% | <0.001 |
| No | 783 | 5 | 0.8% ± 0.3% | 119 | 18.1% ± 1.6% | 81.1 ± 1.6% | |||
| VP‐16/VM‐26 | |||||||||
| Yes | 161 | 2 | 2.3% ± 1.7% | 0.615 | 60 | 40.4% ± 4.1% | 57.4 ± 4.3% | ||
| No | 1305 | 17 | 1.0% ± 0.3% | 250 | 20.9% ± 1.2% | <0.001 | 78.1 ± 1.2% | <0.001 | |
Note: Analyses were only performed for those parameters with available results.
Abbreviations: CI, cumulative incidence; EFS, event‐free survival; Pts, patients; SMN, secondary malignant neoplasm; VM‐26, teniposide; VP‐16, etoposide.